大博医疗(002901.SZ)：2025年三季报净利润为4.25亿元

Core Insights - The company reported a total revenue of 1.876 billion yuan for Q3 2025, with a net profit attributable to shareholders of 425 million yuan [1] - The operating cash flow net inflow was 468 million yuan, indicating strong cash generation capabilities [1] - The company's asset-liability ratio stands at 24.53%, ranking 50th among disclosed peers [1] Financial Performance - Gross margin is reported at 71.23%, reflecting strong profitability [1] - Return on equity (ROE) is at 12.73%, indicating effective use of equity capital [1] - The diluted earnings per share (EPS) is 1.04 yuan [1] Operational Efficiency - Total asset turnover ratio is 0.42 times, suggesting moderate efficiency in asset utilization [1] - Inventory turnover ratio is also 0.42 times, ranking 74th among disclosed peers, indicating potential areas for improvement in inventory management [1] Shareholder Structure - The number of shareholders is 22,800, with the top ten shareholders holding 366 million shares, accounting for 88.36% of total equity [1] - The largest shareholder is Guangxi Dabo Business Communication Venture Investment Co., Ltd., holding 23.41% [1] - Other significant shareholders include Lin Zhixiong (20.8%), Dabo Medical International Investment Co., Ltd. (20.0%), and Lin Zhijun (19.5%) [1]